1. Home
  2. MDB vs RMD Comparison

MDB vs RMD Comparison

Compare MDB & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MongoDB Inc.

MDB

MongoDB Inc.

HOLD

Current Price

$331.46

Market Cap

30.0B

Sector

Technology

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$187.70

Market Cap

28.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDB
RMD
Founded
2007
1989
Country
United States
United States
Employees
N/A
10600
Industry
Computer Software: Prepackaged Software
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.0B
28.4B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
MDB
RMD
Price
$331.46
$187.70
Analyst Decision
Buy
Buy
Analyst Count
34
10
Target Price
$368.67
$292.56
AVG Volume (30 Days)
2.4M
1.4M
Earning Date
06-03-2026
04-30-2026
Dividend Yield
N/A
1.13%
EPS Growth
49.13
N/A
EPS
0.05
N/A
Revenue
N/A
N/A
Revenue This Year
$18.68
$10.60
Revenue Next Year
$17.10
$7.41
P/E Ratio
$6,657.00
$25.61
Revenue Growth
N/A
N/A
52 Week Low
$198.47
$180.27
52 Week High
$444.72
$293.81

Technical Indicators

Market Signals
Indicator
MDB
RMD
Relative Strength Index (RSI) 49.35 38.14
Support Level $309.71 $180.27
Resistance Level $341.95 $260.21
Average True Range (ATR) 25.56 4.80
MACD -5.36 0.21
Stochastic Oscillator 17.60 38.58

Price Performance

Historical Comparison
MDB
RMD

About MDB MongoDB Inc.

Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.

Share on Social Networks: